OneTest Standard is our entry level innovative multi-cancer early detection (MCED) blood test that integrates well-established FDA approved biomarkers with cutting edge AI technology into our unique Lab Developed Test to provide a more advanced look at an individuals risk of being identified over the following 12 months.
OCS will provide physician authorization as well as a blood draw. Both are available at time of purchase. Capillary draw now available for even greater flexibility.
One Tube – 6 Markers
With our patented AI algorithm for greater sensitivity and specificity.
The results provided by OneTest Premium serve as a risk predictor and are not diagnostic for cancer. It is crucial that follow-up actions be determined by a healthcare professional who has access to the individual patient’s complete health history. Biomarkers may register elevated levels for reasons unrelated to cancer, emphasizing the importance of professional interpretation and follow up.
It is essential to note that OneTest Premium is intended to be used by asymptomatic individuals and has not been designed for monitoring disease recurrence.
OneTest Premium is a laboratory developed test (LDT) and has not yet received FDA approval.